New hope for blood cancer patients: Three-Drug combo trial aims to outperform standard chemo

This study is testing whether a new three-drug combination (venetoclax, azacitidine, and gilteritinib) works better than standard chemotherapy for adults with a specific type of acute myeloid leukemia (AML) who are healthy enough for intensive treatment. The trial will enroll 300 newly diagnosed patients with FLT3-mutated AML to compare which approach leads to longer survival without disease progression. Researchers aim to determine if this targeted drug combination can improve outcomes over current standard care.